138 related articles for article (PubMed ID: 36398125)
1. Correlation between imaging features on computed tomography and combined positive score of PD-L1 expression in patients with gastric cancer.
Wang Z; Wang Y; Li X; Li Y; Bu Z; Li Z; Sun Y; Ji J
Chin J Cancer Res; 2022 Oct; 34(5):510-518. PubMed ID: 36398125
[TBL] [Abstract][Full Text] [Related]
2. Correlation of CT parameters and PD-L1 expression status in gastric cancer.
Xu M; Ren T; Deng J; Yang J; Lu T; Xi H; Yuan L; Zhang W; Zhou J
Abdom Radiol (NY); 2024 Apr; 49(4):1320-1329. PubMed ID: 38436699
[TBL] [Abstract][Full Text] [Related]
3. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
Liu X; Choi MG; Kim K; Kim KM; Kim ST; Park SH; Cristescu R; Peter S; Lee J
Pathol Res Pract; 2020 Apr; 216(4):152881. PubMed ID: 32089413
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer.
Yu HY; Li CP; Huang YH; Hsu SJ; Wang YP; Hsieh YC; Fang WL; Huang KH; Li AF; Lee RC; Lee KL; Wu YH; Lai IC; Yang WC; Hung YP; Wang YC; Chen SH; Chen MH; Chao Y
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008382
[TBL] [Abstract][Full Text] [Related]
5. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB
Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489
[TBL] [Abstract][Full Text] [Related]
6. Impact of programmed death-ligand 1 (PD-L1) positivity on clinical and molecular features of patients with metastatic gastric cancer.
Shin M; Ahn S; Jung J; Hyung S; Kim KM; Kim ST; Kang WK; Lee J
Cancer Med; 2023 Sep; 12(18):18633-18642. PubMed ID: 37654198
[TBL] [Abstract][Full Text] [Related]
7. Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases.
Liu DHW; Grabsch HI; Gloor B; Langer R; Dislich B
J Cancer Res Clin Oncol; 2023 Nov; 149(14):13345-13352. PubMed ID: 37491637
[TBL] [Abstract][Full Text] [Related]
8. Remnant gastric cancer: a neglected group with high potential for immunotherapy.
Ramos MFKP; Pereira MA; de Castria TB; Ribeiro RRE; Cardili L; de Mello ES; Zilberstein B; Ribeiro-Júnior U; Cecconello I
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3373-3383. PubMed ID: 32671505
[TBL] [Abstract][Full Text] [Related]
9. Computed Tomography Features of Gastric Cancer Patients With DNA Mismatch Repair Deficiency.
Cao Q; Lai SY; Xu N; Lu Y; Chen S; Zhang XS; Li X
Front Oncol; 2021; 11():619439. PubMed ID: 33816249
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
[TBL] [Abstract][Full Text] [Related]
11. [Expression level and prognostic value of PD-L1 in microsatellite instability-high gastric cancer].
Wang XY; Hu YJ; Dong K; Zhao C; Huang XZ; Lian SY; Sun Y
Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1114-1119. PubMed ID: 33152814
[No Abstract] [Full Text] [Related]
12. [Preoperative assessment value of spectral CT quantitative parameters in lymph node metastasis of gastric cancer].
Chai Y; Gao J; Xing J; Lyu P; Liang P; Chen X
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Mar; 20(3):309-314. PubMed ID: 28338166
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs.
Park Y; Koh J; Na HY; Kwak Y; Lee KW; Ahn SH; Park DJ; Kim HH; Lee HS
Cancer Res Treat; 2020 Jul; 52(3):661-670. PubMed ID: 32019283
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan.
Yoshida T; Ogura G; Tanabe M; Hayashi T; Ohbayashi C; Azuma M; Kunisaki C; Akazawa Y; Ozawa S; Matsumoto S; Suzuki T; Mitoro A; Fukunaga T; Shimizu A; Fujimoto G; Yao T
Cancer Biol Ther; 2022 Dec; 23(1):191-200. PubMed ID: 35220884
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of programmed death-ligand 1 protein expression between primary tumors and lymph node metastatic lesions in oral squamous cell carcinoma].
Xia RH; Hu YH; Zhang CY; Xu SM; Li J
Zhonghua Kou Qiang Yi Xue Za Zhi; 2022 Nov; 57(11):1113-1118. PubMed ID: 36379889
[No Abstract] [Full Text] [Related]
16. Interpretation of PD-L1 expression in gastric cancer: summary of a consensus meeting of Korean gastrointestinal pathologists.
Ahn S; Kwak Y; Kwon GY; Kim KM; Kim M; Kim H; Park YS; Oh HJ; Lee K; Lee SH; Lee HS
J Pathol Transl Med; 2024 May; 58(3):103-116. PubMed ID: 38653580
[TBL] [Abstract][Full Text] [Related]
17. The heterogeneity of PD-L1 protein in gastric cancer: expression and distribution characteristics.
Wang Y; Wang N; Huang Z; Lu Z; Guo T; Meng G
Heliyon; 2022 Dec; 8(12):e12456. PubMed ID: 36593830
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression-related PI3K pathway correlates with immunotherapy efficacy in gastric cancer.
Liu L; Niu L; Zheng X; Xiao F; Sun H; Deng W; Cai J
Ther Adv Med Oncol; 2023; 15():17588359231205853. PubMed ID: 37868079
[TBL] [Abstract][Full Text] [Related]
19. Role of CT in the prediction of pathological complete response in gastric cancer after neoadjuvant chemotherapy.
Wang ZL; Li YL; Li XT; Tang L; Li ZY; Sun YS
Abdom Radiol (NY); 2021 Jul; 46(7):3011-3018. PubMed ID: 33566165
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
Schulz GB; Todorova R; Braunschweig T; Rodler S; Volz Y; Eismann L; Pfitzinger P; Jokisch F; Buchner A; Stief C; Mayr D; Casuscelli J
Urol Oncol; 2021 Oct; 39(10):734.e1-734.e10. PubMed ID: 34261585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
